普拉德福韦治疗慢性乙型肝炎:多中心双盲随机非劣效2期试验第24周结果
这项2期试验将240例慢乙肝患者随机分配至普拉德福韦30、45、60、75 mg组或替诺福韦二吡呋酯(TDF)300 mg组。第24周时,普拉德福韦各剂量组HBV DNA降幅与TDF相当,45、60、75 mg组HBeAg清除率高于TDF组,所有治疗安全耐受良好。
要点
- 普拉德福韦各剂量组第24周HBV DNA降幅与TDF相当。
- 45、60、75 mg组HBeAg清除率高于TDF组。
- 所有治疗安全耐受良好,未报告治疗相关严重不良事件。
核心结论
- 普拉德福韦与TDF对HBV DNA水平的降幅相当,所有治疗安全且耐受良好。
研究设计与样本
- 多中心、双盲、随机、非劣效2期试验,共240例慢性乙型肝炎患者随机接受治疗,每组48例。
主要发现
- 第24周HBV DNA较基线降幅:普拉德福韦30、45、60、75 mg组分别为5.40、5.34、5.33、5.40 log10 IU/mL,TDF组为5.12 log10 IU/mL。
- HBeAg清除率:普拉德福韦45、60、75 mg组分别为12%、6%、9%,TDF组为3%。
- TDF组血清肌酐升高较普拉德福韦30和45 mg组更显著,各组血清磷酸盐水平相当。
- 大多数不良事件为轻度(1级),未报告治疗相关严重不良事件。
临床怎么用
- 普拉德福韦各剂量第24周HBV DNA降幅与TDF相当,支持进一步开展3期研究确定最佳剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pradefovir is a liver-targeted prodrug of adefovir, a nucleoside/nucleotide analogue with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30, 45, 60, or 75 mg) versus tenofovir disoproxil fumarate (TDF; 300 mg) and aimed to identify the most appropriate dose of pradefovir for the forthcoming phase 3 study. METHODS: Treatment-naive and experienced (not on treatment >6 months) patients with chronic hepatitis B were eligible. RESULTS: A total of 240 participants were randomized and treated in the study (48 per group). Approximately 80% were hepatitis B e antigen (HBeAg) positive, and 10% had liver cirrhosis. The reductions from baseline in HBV DNA levels achieved at week 24 were 5.40, 5.34, 5.33, and 5.40 log10 IU/mL, with pradefovir doses of 30-, 45-, 60-, and 75-mg, respectively, compared with 5.12 log10 IU/mL with TDF. However, HBeAg loss was attained by more participants who received 45-, 60-, or 75-mg pradefovir than by those receiving TDF (12%, 6%, and 9% vs 3%). The TDF group exhibited a more significant increase in serum creatinine than the pradefovir 30- and 45-mg groups, and serum phosphate levels were comparable among all groups. Most adverse events (AEs) were mild (grade 1). No treatment-related severe AEs were reported. Overall, AEs and laboratory abnormalities were comparable to those in the TDF group. CONCLUSIONS: Pradefovir and TDF exhibited comparable reductions in HBV DNA levels. All treatments were safe and well tolerated. CLINICAL TRIALS REGISTRATION: NCT00230503 and China Drug Trials CTR2018042.
引用
- Gao Y, Kong F, Song X, et al. Pradefovir Treatment in Patients With Chronic Hepatitis B: Week 24 Results From a Multicenter, Double-Blind, Randomized, Noninferiority, Phase 2 Trial. Clin Infect Dis. 2022. PMID: 34487151. doi:10.1093/cid/ciab763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。